Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Chronic kidney disease

KDIGO CKD–MBD guideline update: evolution in the face of uncertainty

Nature Reviews Nephrology volume 13, pages 600–602 (2017)Cite this article

Subjects

Management of mineral and bone disorders in patients with chronic kidney disease (CKD–MBD) requires an understanding of the complex interactions among ions, hormones and their target organs. Since publication of the KDIGO CKD–MBD guideline in 2009, our understanding of disease pathophysiology has improved; however, a paucity of high-quality clinical evidence to support specific interventions remains. Using available data, KDIGO has now updated diagnostic and therapeutic recommendations for patients with CKD–MBD.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Revised recommendations from the 2017 KDIGO CKD–MBD guideline.

References

  1. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group. KDIGO 2017 Clinical Practice Guideline update for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int. Suppl. 7, 1–59 (2017).

  2. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int. Suppl. 113, S1–S130 (2009).

  3. Bushinsky, D. A. Contribution of intestine, bone, kidney, and dialysis to extracellular fluid calcium content. Clin. J. Am. Soc. Nephrol. 5, S12–S22 (2010).

    Article  CAS  Google Scholar 

  4. Spiegel, D. M. & Brady, K. Calcium balance in normal individuals and in patients with chronic kidney disease on low- and high-calcium diets. Kidney Int. 81, 1116–1122 (2012).

    Article  CAS  Google Scholar 

  5. Hill, K. M. et al. Oral calcium carbonate affects calcium but not phosphorus balance in stage 3–4 chronic kidney disease. Kidney Int. 83, 959–966 (2013).

    Article  CAS  Google Scholar 

  6. Wang, A. Y. et al. Effect of paricalcitol on left ventricular mass and function in CKD—the OPERA trial. J. Am. Soc. Nephrol. 25, 175–186 (2014).

    Article  CAS  Google Scholar 

  7. Thadhani, R. et al. Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial. JAMA 307, 674–684 (2012).

    Article  CAS  Google Scholar 

  8. Naylor, K. L. et al. Comparison of fracture risk prediction among individuals with reduced and normal kidney function. Clin. J. Am. Soc. Nephrol. 10, 646–653 (2015).

    Article  Google Scholar 

  9. West, S. L. et al. Bone mineral density predicts fractures in chronic kidney disease. J. Bone Miner. Res. 30, 913–919 (2015).

    Article  Google Scholar 

  10. Toussaint, N. D., Lau, K. K., Strauss, B. J., Polkinghorne, K. R. & Kerr, P. G. Effect of alendronate on vascular calcification in CKD stages 3 and 4: a pilot randomized controlled trial. Am. J. Kidney Dis. 56, 57–68 (2010).

    Article  CAS  Google Scholar 

Download references

Acknowledgements

W.C. is supported in part by the American Society of Nephrology Carl W. Gottschalk Research Grant. D.A.B. is supported in part by a NIH grant (2R01DK075462). Both researchers receive grant support from the Renal Research Institute.

Author information

Authors and Affiliations

  1. Department of Medicine, University of Rochester School of Medicine and Dentistry,

    Wei Chen

  2. Department of Medicine and Department of Pharmacology and Physiology, University of Rochester School of Medicine and Dentistry, 601 Elmwood Avenue, BOX 675, Rochester, 14642, New York, USA

    David A. Bushinsky

Authors
  1. Wei Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. David A. Bushinsky
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to David A. Bushinsky.

Ethics declarations

Competing interests

D.A.B. is a consultant for Relyspa, Amgen, Sanofi/Genzyme, Vifor, and Tricida and has an equity interest in Amgen and Tricida. W.C. declares no competing interests.

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Chen, W., Bushinsky, D. KDIGO CKD–MBD guideline update: evolution in the face of uncertainty. Nat Rev Nephrol 13, 600–602 (2017). https://doi.org/10.1038/nrneph.2017.118

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrneph.2017.118

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing